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Abstract
The incidence of obesity and type diabetes 2 has increased dramatically resulting in an increased interest in its biomedical relevance. However,
the mechanisms that trigger the development of diabetes type 2 in obese patients remain largely unknown. Scientific, clinical and pharmaceuti-
cal communities are dedicating vast resources to unravel this issue by applying different omics tools. During the last decade, the advances in
proteomic approaches and the Human Proteome Organization have opened and are opening a new door that may be helpful in the identification
of patients at risk and to improve current therapies. Here, we briefly review some of the advances in our understanding of type 2 diabetes that
have occurred through the application of proteomics. We also review, in detail, the current improvements in proteomic methodologies and new
strategies that could be employed to further advance our understanding of this pathology. By applying these new proteomic advances, novel
therapeutic and/or diagnostic protein targets will be discovered in the obesity/Type 2 diabetes area.
Keywords: diabetes mellitus type 2 obesity proteomics biomarkers
Introduction
The incidence of diabetes mellitus type 2 (DM2) is increasing at an
alarming rate world-wide. This is due, in part, to the dramatic rise in
the obesity epidemic as DM2 is a comorbidity frequently seen in
obese patients [1]. Because not all obese patients develop DM2 and
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not all patients suffering from DM2 are obese or overweight [2], it is
of interest to understand the mechanisms underlying the association
between these two entities to predict which patients are at higher risk
for developing this disease, and possibly for the development of pre-
ventative therapies. DM2 appears as a result of insulin resistance.
During the ontogeny of this disease, the pancreas begins to produce
greater amounts of insulin to maintain euglycemia that collectively
overcomes this resistance. But as time advances, sufficient insulin
levels cannot be maintained to control normal levels of glycemia. The
clinical characteristics of DM2 appear several years after the onset of
this process during which time the person is asymptomatic. Once
DM2 clearly appears, it must be attended immediately as it is very dif-
ficult and practically impossible to reverse the disease progression. In
any event, factors such as exercise and diet can ‘help’, as it is of
utmost importance to properly control DM2 through life style, and
early intervention of the factors previously mentioned may result in
normal glucose levels. Thus, early detection, or even more impor-
tantly, the possibility of avoiding DM2 onset would be of extreme ben-
efit.
The alteration of protein structure, function, production and inter-
actions, in part if not completely, contributes to the underlying mech-
anism of many diseases including diabetes [3]. Comprehension of
pathological-mechanisms whereby molecular and environmental
actions lead to the development and progress of diabetes is important
for the prevention and treatment of this disease. In such an endeav-
our, approaches such as genomics, metabolomics and proteomics
are being applied to identify more specific biomarkers for DM2 for its
early detection, management and for devising new therapies. In this
review, we will focus on the use of proteomics for the identification of
novel biomarkers, and perhaps, therapeutic targets for the identifica-
tion and subsequent treatment of DM2. As in any research study, effi-
cient and up-to-date methods must be established and used for
selection and proper handling of the clinical samples and data [4].
Simply defined, proteomics is the large-scale study of proteins,
particularly of their structures and functions [5, 6]. Proteins are vital
parts of living organisms, as they are the main components of all cel-
lular processes. The term proteomics was first coined in 1997 [7] as
an analogy with genomics, the study of an organism’s genome. The
word proteome is a blend of protein and genome and was coined by
Marc Wilkins in 1994 while working on the concept as a PhD student
[8]. The proteome is the entire set of proteins [8] produced or modi-
fied by an organism or system. This will vary with time as a result of
distinct requirements or stresses that a cell or organism encounters.
Proteomics allows the study of the entire set of proteins, produced or
modified by an organism or system and it varies with time and a vari-
ety of environmental factors. Indeed, it is formed on the basis of
research and development of the Human Genome Project [9, 10].
Thus, while the genome is static the proteome is dynamic. It is also a
fundamental component of functional genomics. While proteomics
generally refers to the large-scale experimental analysis of proteins in
a given cell/tissue/organism, techniques used in the studies can also
be applied to protein identification and purification. One of the key
methodologies used in this area is mass spectrometry [11]. We will
discuss in detail the sample preparation step as a key issue for clinical
proteomic research in the following section.
Sample preparation
The sample preparation of body fluids (blood, serum, urine and sali-
vary) or tissues (e.g. adipose) is an extremely important pre-requisite
for achieving robust and reproducible data via proteomics. Once the
body fluids and/or tissues have been obtained for future proteomic
analyses, they must be frozen rapidly (i.e. at 80°C in a bio-banking
system) usually in aliquots distributed in several vials to avoid sample
deterioration from repeated freeze–thaw cycles. When working with
adipose tissue samples, the selection of the representative areas from
the human body is extremely important according to the clinical
research goal. Tissue handling is also of paramount importance as
different tissues will require different homogenization and processing
protocols. Several examples are explained in the following sections
and in Table 1. For clinical proteomic purposes, changes can take
place in proteome assays that can easily modify experimental results.
For example, contamination of protein-samples can cause results to
be skewed, as artefacts and/or contaminants can mask low expressed
proteins during mass spectrometry (MS) analysis, and they can also
give rise to poor protein-separation during electrophoresis and chro-
matography, and in addition, artefacts can interact with the given pro-
tein, thus changing the 3D-structure [12].
There are many steps that can be taken in protein handling and
storage processes, which may help to minimize any damage and, in
turn, maximize accuracy of results. Crucial steps in the process are to
use anti-proteases and anti-phosphatases, and to freeze the protein
sample quickly after harvesting in several vials. A very common pre-
mise is that ‘there are no routine sample preparation-protocols’ for a
given proteomic experiment; it is always necessary to optimize them
according to the clinical goals and according to the designed proteo-
mic strategies to be used. In any event, optimized protocols for a
given sample or samples from the same clinical assays can be used
routinely. Moreover, several international laboratories [from Human
Proteome Organization (HUPO), EUPA and SeProt] are standardizing
specific protocols for storing clinical samples apart from those for
analysis via proteomics and MS using reproducible protocols from
different laboratories. This is important when we carry out analyses
and the data are coming from different experiments from different
laboratories [13–15].
Although the amount of protein obtained from patient samples
can be very low, clinical samples allow highly valuable data to be
achieved even with a limited amount of samples. Once the type of
sample to be used has been selected, it is necessary to optimize the
protocol for tissue disruption/cell-lysis or for the isolation of the pro-
teins from body fluids using commercial reagents including protease
and phosphatase inhibitors. When analysing serum/plasma, it may be
necessary to use an albumin/IgG depletion kit to identify proteins
whose concentration is low [15].
We have found that many proteins do not exist as a single form
but as isoforms probably generated by post-translational modifica-
tions (PTM) of a given protein. Thus, for any proteomic protocol
used, one must be knowledgeable about protein isoforms. In certain
instances, it is also recommended that the purified complex mixture
of proteins be dilapidated. Additionally, one often analyses a given tis-
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sue along with serum or urine. This type of complementary data may
or may not be easily interpreted but many clinical research studies
show that analysing both types of samples offers the possibility to
explain linked biological processes. Additionally, the selection of a
given proteomic platform must be made according to the goal of the
experiment [16, 17]. For example, high-throughput–proteomic strate-
gies may be useful for discovery of biomarkers specifically related to
various stages of obesity and DM2, and they may help to improve
current treatments and innovative therapies. On the other hand, once
the target proteins are selected by the discovery phase of the
research, analysis of those proteins in the complex mixture of biologi-
cal samples can be conducted by selected reaction monitoring (SRM)
or multiple reaction monitoring (MRM) assays. The sample-prepara-
tion of body fluids is a tedious but critical step in obtaining reliable
results [16–19]. For example, urine contains low levels of proteins
compared to blood and a large amount of sample and/or a concentra-
tion procedure may be required for analyses. The timing of the sam-
ple collection may influence the results because the protein
composition of body fluids may be different according to the different
stages of the treatment for each patient. Indeed, we hypothesize that
the serum from a patient suffering DM2 may contain different protein
patterns at diagnoses (t0) during the treatment (t1) and also at the
end of the therapy (t2). Nevertheless, there is no reference protein-
map for DM2 or for obesity; thus, if we are able to ‘build’ the protein-
pattern reference map of obesity and DM2 compared to healthy con-
trols, we should improve our understanding of these pathologies.
Clinical application of proteomics, applied according to space
(serum, urine, blood) and time (diagnoses, treatment and/or cured
states), can be used to study the evolution of patients suffering obes-
ity and DM2, to unravel the mechanisms involved in disease progres-
sion. In the end, we hope that the patients will benefit.
In the following sections, we discuss specific details useful for
carrying out obesity and DM2 proteomic research.
Special issues concerning tissue/
blood sampling
As stated above, sample integrity and storage are key factors for
obtaining efficient and reproducible data. Within the last decade, the
quantity and quality of stored samples are high because of the crea-
tion of biobanks including sample collection procedures. This implies
that the samples are kept intact, preserving their chemical and physi-
cal characteristics that may ultimately result in data indicative of their
functions and/or roles within the cell. Thus, different types of samples
(blood, urine, tissues) from the patients with different pathologies are
available for study [18, 19] or can be collected and properly stored in
an individual laboratory’s biobank.
Another important step is related to the standardization of pro-
tocols for data acquisition from different biobanks so that different
disease states and/or changes throughout time can be compared
[20]. If one of the main goals is to establish a long-term repository
of biological/clinical samples and to make these samples available
to multiple scientific studies, then specific protocols must be used.
For example, if we have a particular interest in diabetes, fasting
samples should be collected and stored. Additionally, a patient’s
phenotypic data must be recorded including age, sex, weight, BMI,
fasting glucose and other clinically important parameters. These
data should be obtained at diagnoses and at different states
throughout the disease. Protocols to store clinical samples should
provide clear information on how and when the samples were col-
lected, processed and organized to ensure their long-term integrity
for the study of a given disease [21].
Serum samples
One of the major difficulties in studying the serum proteome is
that two major groups of serum proteins, albumin and immuno-
globulins, comprise approximately 95% of the total, while the
remaining 5% belongs to a variety of other protein types including
cytokines, hormones, enzymes and cytoplasmic and nuclear pro-
teins. Those highly abundant proteins may generate substantial
background in any proteomic analysis and may mask the signifi-
cant changes in proteins of interest. Albumin and IgG can be
removed from serum using affinity chromatography to refine the
identification of biomarkers (low expressed proteins) for a given
pathology [22]. However, since albumin interacts with many blood
components, it is possible that by removing albumin, one may
inadvertently remove important proteins that are important to a
given pathology, in this case DM2.
The lipids contained in serum can have an important role in spe-
cific pathologies, such as hyperlipidemia, cardiovascular diseases,
etc., as they can interact with serum proteins. In some cases, it is
necessary to remove these lipids to identify the required proteins.
Fractionating the serum via centrifugation allows one to then separate
chylomicrons, very low density lipoproteins (such as VLDLPs) from
the total protein sample [23–25].
Results of proteomic analyses comparing a diseased versus
healthy state and the different stages of the disease can ultimately
identify putative therapeutics and/or therapeutic targets as well as
diagnostic biomarkers. It has been suggested that the concentration
of specific proteins in serum can be useful for the early detection of
insulin resistance and that this may even be possible before the
appearance of the symptoms [23, 24, 26]. Thus, identification of dif-
ferentially expressed serum proteins could be potentially important
for the prevention and treatment of DM2, even in obese children [26–
28].
Proteomic methodologies
The most significant breakthrough in proteomics has been the use of
MS for the identification of proteins directly obtained from clinical
samples or from samples in which the proteins were previously sepa-
rated by two dimensional (2DE) gel electrophoresis or chromatogra-
phy. Typical MS based identification of a protein utilizes tryptic
digestion [29] prior to MS analysis to improve the accuracy or mass
measurements. Mass spectrometry ionizes protein or peptide sam-
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ples and measures their mass-to-charge ratios. Two ionization meth-
ods often employed are matrix-assisted laser desorption/ionization
(MALDI) and electrospray ionization (ESI). The time –of –flight (TOF)
analyzer is often used with MALDI. The TOF analyzer accelerates the
ions in an electric field and measures the time they take to reach the
detector. If the sample’s charge is the same, velocity is inversely
related to their masses. The quadrupole mass filters are used with
ESI. It consists of four parallel metal rods. By controlling electric field
within the four rods by a radio frequency voltage, only ions with a cer-
tain mass-to-charge ratio can be selected and reach the detector. The
quadrupole ion trap works similar to the quadrupole filter, but instead
of passing a single ion species through, it traps ions and releases
them sequentially.
Tandem MS is an array of MS that enables peptide sequencing.
The first MS isolates a peptide to be analysed and the second MS
fragments the peptide by collision-induced dissociation (CID) by a
neutral molecule such as nitrogen. Finally a third MS measures mass-
to-charge ratio of the resulting fragments [30]. A series of three quad-
rupoles can be used in the same manner. Since CID fragments a pep-
tide randomly at the peptide bonds, sequence information can be
obtained by analysing the resulting mass spectrum.
Mass spectrometry can be coupled to chromatography. For
selected proteomic analyses, liquid chromatography (LC) is often
used to separate proteins or peptides, then masses of the separated
peptides are determined by MS. For LC-MS analyses only microgram
quantities of a sample are necessary for its characterization [31, 32].
The 2DE gel-based technique is a very useful tool for protein sep-
aration [33], where during the first dimension proteins are separated
according to their net charge by isoelectric focusing via immobilized
pH gradient gel-strips. Subsequently, during the second dimension,
proteins from the gel-strips are resolved according to their molecular
weight using SDS-PAGE. 2DE can be very useful as post-translation-
ally modified protein isoforms are typically revealed. These protein
isoforms are not easily resolved by the other methods. A drawback of
2DE is related to gel-to-gel variations and the necessity of a large
amount of samples (usually from 300 lg to 1 mg) for analysis.
Moreover, the detection limit of proteins in 2DE is in the microgram
range. In spite of this, interesting 2DE studies have resulted in impor-
tant data pertaining to DM [34].
In addition, 2DE-gels have been coupled to differential in-gel elec-
trophoresis (DIGE). In 2DE-DIGE, the protein samples are labelled
with fluorescent dyes and then separated by 2D-PAGE. Different bio-
logical samples are labelled with different fluorescent dyes, mixed
together and separated in the same gel. The gels are scanned by laser
and the images of 2D-PAGE gels for multiple samples are obtained
from the single gel. 2D-DIGE overcomes gel-to-gel variations and
enables comparisons of multiple samples directly. Although 2DE-
DIGE is a more refined strategy than 2DE, the detection limit remains
at 0.5 lg.
In contrast to 2DE, LC-MS is a gel-free tool where digested
proteins or tryptic peptides can be separated according to their
physical and chemical properties (i.e. hydrophobicity, charges and
pH). LC-MS has a higher sensitivity than 2DE-gels allowing the
detection of proteins present at low levels and at the same time
highly expressed proteins. Nevertheless, high abundant proteins
such as some serum proteins (albumin) must be depleted to refine
the resulting data [34].
Ion exchange chromatography is a popular methodology that
allows the purification of proteins as well as other charged molecules.
In strong cation exchange chromatography (SCX) positively charged
molecules are attracted to a negatively charged solid support. Con-
versely, in strong anion exchange chromatography (SAX), negatively
charged molecules are attracted to a positively charged solid support.
Ion exchange chromatography consists of a methodology to separate
molecules based on differences related to their accessible surface
charges. This technique is extensively applied in the pre-fractionation
and/or purification of target protein(s) from crude biological samples.
It involves the reversible adsorption of charged molecules to immobi-
lized ion groups on a matrix of an opposite charge, thus, interactions
among molecules and active-sites on the membrane support, occur
in a convective manner via pores. Once the sample is loaded and
equilibrium is reached, the molecules reach the adsorption step
because of appropriate charge and displace the counter ions. Finally,
they bind reversibly to the matrix. Generally, the unbound materials
will pass by the column with the void volume. In the third stage, via
increasing the ionic strength of the eluting buffer, substances are
removed from the column. Also, high protein recovery rates with
intact biological activity are produced by the relatively mild binding
and eluting conditions of this separation method. Furthermore, SCX
and SAX can be easily coupled to MS [35, 36].
Analysis of protein phosphorylation
It is very important to analyse phosphorylated proteins in clinical
research, as they may imply new targets for drug/therapy innovations.
We will detail it in a simple manner via the most currently useful tools.
Sequential elution of (IMAC) followed by TiO2
Immobilized metal affinity chromatography (IMAC) and titanium diox-
ide (TiO2) are metal-beads that can be packed to construct manual
metal-affinity chromatography-tips to isolate primarily multi-phos-
phopeptides via IMAC and mono-phosphopeptides via TiO2 [35].
Thus, this tool is useful for the isolation of mono and multi-phosphor-
ylated protein/peptides from a biological complex-analyte in a single
experiment. The basic principle relies on the fact that metals con-
tained in IMAC and TiO2 carry positive charges and link the negatively
charged-phosphopeptides. TiO2, IMAC and ZrO2 are all useful for
phospho-enrichments, but Thingholm et al. [37] demonstrated a
higher yield from SIMAC when purifying mono and multi-phospho-
peptides in a single experiment; thus we recommend SIMAC as it
works well for clinical samples. The most common techniques for
enrichment for individual and/or global phosphorylation are IMAC and
TiO2 [38], which are based on the high affinity of positively charged
metal ions. However, conversion of carboxylate groups to esters
effectively eliminates non-specific retention of non-phosphorylated
peptides, although this constitutes a drawback because of the
increased complexity in the subsequent MS analysis.
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During the last 10 years, TiO2 has emerged as the most common
of the metal oxide affinity chromatography based phosphopeptide
enrichment methods. This technique offers increased capacity com-
pared to IMAC resins to bind and elute mono-phosphorylated pep-
tides. TiO2 exploits the same principle as IMAC, and is similarly prone
to non-specific retention of acidic non-phosphorylated peptides. How-
ever, when loading peptides in 2,5-dihydroxybenzoic acid [39], gly-
colic and phthalic acids, non-specific binding to TiO2 is reduced,
thereby improving phosphopeptide enrichment without a chemical
modification of the sample. TiO2 is often considered to be inter-
changeable with IMAC. It works on similar levels of sample quantity
(e.g. micrograms of protein) for the identification of phosphorylation-
sites by MS analysis. Recently, SIMAC [39–41] appeared as a phos-
phopeptide enrichment tool that exploits the properties of IMAC cou-
pled to TiO2, making it possible to carry out more refined studies.
Another phosphopeptide enrichment procedure prior to MS analy-
sis is ZrO2 [42] and its principle is based on metal affinity chromatog-
raphy like IMAC and TiO2. ZrO2 permits the isolation of single
phosphorylated peptides in a more selective manner than TiO2. It has,
in fact, been successfully used in the large-scale characterization of
phosphoproteins [43–46]. Furthermore, strategies that consist of
fractionating and subsequently enriching phosphopeptides are based
on strong cation/anion exchange (SCX and SAX) chromatography and
HILIC interaction chromatography. Calcium phosphate precipitation is
also a useful pre-fractionation step to simplify and enrich phospho-
peptides from complex samples which can be coupled to IMAC [46].
Isobaric tag for relative and absolute
quantitation
This technique allows the relative and absolute quantification of 2 to 8
complex-samples at the same time [47]. It uses a multiplexed iso-
baric chemical tagging-reagent. This tag permits multiplexing of 2 to
8 complex-protein samples and produces identical MS/MS sequenc-
ing ions for all 8 versions of the same derived tryptic peptide. Quanti-
fication and analyses are performed via comparing the peak-areas
and peak-ratios in the MS/MS mode. The reporter-ions used are from
114 to 117 Da and from 113 to 119 and 121 Da. To carry out protein
expression level studies, it can be a good option to apply isobaric tag
for relative and absolute quantitation (iTRAQ), even though stable iso-
tope labelling by amino acids in cell culture (SILAC, when using cell
lines) and/or MRM or SRM can also be successfully employed (see
below) [48, 49].
SILAC is another approach for in vivo incorporation of a label into
proteins for subsequent MS-quantitative analysis. The identification
step is currently carried out in MS/MS mode. Its principle is based on
metabolic incorporation of a given ‘light’ or ‘heavy’ form of the amino
acid into the proteins. Amino acids are incorporated via substituted
stable isotopic forms such as deuterium, 13C and 15N. Basically, dur-
ing SILAC experiments, two cell-populations are grown in a culture
media that is identical except that one contains the ‘light’ label and
the second one the ‘heavy’ label. These labels allow the comparison
of two physiological conditions (e.g. healthy versus ill). Two condi-
tions are distinguished via the labelled analogue amino acid that was
added to the culture media. The newly synthesized proteins within
cells have the same physical and chemical properties except for the
mass differences as a result of the isotope [50].
Selected reaction monitoring or multiple reaction
monitoring
This is a quantitative proteomics MS/MS-based tool. When using ESI,
first, a peptide precursor is selected and isolated to obtain an ion pop-
ulation that represents ‘the precursor’. Next, the ion population is
fragmented to produce product ions or ‘daughter ions’. The signal-
intensity of the fragmented ions represents the abundance of peptides
and/or proteins for a given sample. Indeed, this method allows for
absolute quantitative data. Selected reaction monitoring or MRM is
carried out in specific mass spectrometers called ‘tripe quadrupole’
and ‘ion traps’. The sensitivity and specificity of such strategy is
extremely high. In SRM assays, two mass analyzers are used as static
mass-filters to monitor a particular fragment-ion from a selected pre-
cursor-ion. The resulting selectivity from the two filtering stages cou-
pled to the high-duty cycle data in quantitative assays allows for
extremely high sensitivity [51–60] (Fig. 1 shows in a simple scheme
of SRM/MRM useful for metabolic research.
Label-free quantification
This is a MS-based method that allows the determination of the rela-
tive amount of protein from 2 or more complex samples [61]. Label-
free quantification does not use a stable isotope containing com-
pound to chemically bind to the proteins. In a label free quantitative
proteomic analysis, protein mixtures are analysed directly and sam-
ples are compared to each other after independent analyses. As a
result, there is no mixing of samples, so that higher proteome cover-
age can be achieved and there is no limit to the number of experi-
ments that can be compared [62]. Moreover, label-free approaches
may be divided into two main groups by the way that the abundance
of a peptide is measured. The first group comprises methods that are
based on the ion count and compare either maximum abundance or
volume of ion count for peptide peaks at specific retention times
between different samples. Since ionized peptides elute from a
reversed-phase column into the mass spectrometer, their ion
intensities can be measured within the given detection limits of the
experimental setup [43–45, 63–68] (Fig. 2 shows in a simple manner
the scheme of Label-free useful for metabolic research).
Electrospray ionization and tandem mass
spectrometry MS-n (Nano-ESI-MSn)
Tandem MS [69], ESI coupled with CID and MS/MS potentially repre-
sents one of the most sensitive, discriminating and direct methods
for the qualitative and quantitative high-throughput analysis of sub-
picomole amounts of protein. Nano-ESI-MS/MS allows identification
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of the previously labelled and isolated proteins/peptides (and phos-
pho-proteins/peptides) coming from complex samples (i.e. blood
and/or CSF) and subsequently, data analyses of the quantified (from
iTRAQ label) and modified residues (from isolation SIMAC) must be
conducted via, for example, Matrix-Science Mascot searching (http://
www.matrixscience.com/cgi/search_form.pl?FORM-
VER=2&SEARCH=MIS).
Through the previously mentioned tools, we can achieve: (i) iden-
tification (ID) of protein candidate biomarkers, (ii) analyse how the
intracellular signalling -networks are activated/deactivated via phos-
phorylation during disease progression and (iii) determine which pro-
teins and phosphoproteins or other PTMs are up and/or down-
regulated in several clinical states (healthy or ill). The resulting data is
specific for a given time and/or disease state (i.e. after diagnosis, dur-
ing treatment) of a specific patient/s and according to each different
type of sample (blood, sera, urine) as the proteome is dynamic (space
and time). Finally, the resulting identified protein-biomarkers can be
validated by ELISA and/or western blotting and via SRM/MRM
A
B
C
Fig. 1 Scheme of SRM/MRM useful for
metabolic research. SRM or MRM for
quantitative assays consists of: (A) follow-
ing, for example, ionization ESI type, (B) a
peptide precursor is first isolated to obtain
a substantial ion population of mostly the
intended species. This population is then
fragmented to yield product ions (C)
whose signal abundances are indicative of
the abundance of the peptide in the sam-
ple. SRM can be carried out on a triple
quadrupole, where mass-resolving Q1 iso-
lates the precursor, Q2 acts as a collision
cell and mass-resolving Q3 is cycled
through the product ions which are
detected upon exiting the last quadrupole.
A precursor/product pair is often referred
to as a transition.
Fig. 2We suggest to perform this scheme
of Label-free quantification useful for met-
abolic research. (A) Peptide signals are
detected at the MS1 level and are distin-
guished from chemical noise/background
by their characteristic isotopic pattern. (B)
These patterns are then followed via the
retention time dimension and are used to
rebuild a chromatographic elution-profile
of the mono-isotopic peptide mass. (C–E)
The total ion current of the peptide signal
is then integrated and used as a quantita-
tive measurement of the original peptide
concentration. For each detected peptide,
all isotopic peaks are first found and the
charge state is then assigned. Label-free
can be carried out via Fourier Transform
Ion Cyclotron Resonance (FTICR) or Orbi-
trap.
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assuming that an antibody is available for a given protein [70–72]. To
summarize, to obtain reliable and reproducible biomarker data, it is
always necessary to standardize protocols for the collection, han-
dling, storage and processing of samples for subsequent proteomic
analyses using any of the procedures described above. These tools
allow the analysis of hundreds of proteins at a given time in a very
small sample size with high sensitivity. The main difference among
these current techniques is related to the sensitivity, the detection-
level of the selected method [73–80].
Identification of proteins
Mascot Server (http://www.matrixscience.com/) is commonly used
for identification, characterization and quantification of the resulting
proteins after MS results have been collected. It allows free searches
and contains protein sequence databases online from all organisms
analysed to date. Through Mascot it is also possible to validate the
identified protein-biomarkers from the clinical proteomic research
study via manual inspection of all the spectra. Manual validation of
spectra is required by the best proteomic journals to ensure the high
quality of data. New and efficient bioinformatic software is routinely
appearing on the market to carry out statistics and validation, espe-
cially for high-throughput analysis; thus, the validation-step can be
developed more efficiently. Interesting and useful bioinformatic tools
for proteomics research are well-established in other reviews [80,
81].
Thus, it is obvious that the methodology available to perform pro-
teomics and phosphoproteomic studies has advanced dramatically in
recent years, to improve our understanding of intracellular signalling
networks. These methodological advances are now beginning to be
applied to studies of DM2 and the identification of new biomarkers.
Figure 3 shows, in a simple manner, the basic work-flow useful for
metabolic research (Fig. 3). Below we briefly review some of the most
relevant studies in diabetes using proteomic approaches.
Current and relevant studies of DM
and obesity using proteomic
approaches
Yang et al. [82], carried out 2DE of peritoneal dialyzed samples. They
were able to visualize more than 300 protein-spots, from which 13
protein spots were selected to be excised and the corresponding pro-
teins were digested and analysed by reverse-phase nano-ultra perfor-
mance LC-ESI-MS/MS. The resulting data confirmed 10 spots/
proteins with significant differential expression between the DM and
chronic glomerulonephritis peritoneal dialyses samples. These
authors state that the differentially expressed proteins identified in
their study may not be new biomarkers. However, they also indicate
possible targets for drug treatment and protein profiles that could be
predictors of peritonitis, indicating the necessity for validation studies
in the future. A possible way to validate the resulting identified pro-
tein-biomarkers from obesity and DM2 samples during clinical prote-
omic research studies is via: (i) ELISA and/or western blotting (using
specific antibodies (Abs) for the identified potential biomarkers-) and
(ii) via SRM/MRM [4]. Selected reaction monitoring or MRM is a
method of MS/MS that allows one to monitor target peptides within a
complex mixture of tryptic peptides. For example, proteins A1 and B2
are discovered as biomarkers for DM2 at diagnosis in obese patients,
while proteins C3 and D4 are biomarkers for DM2 during treatment
Fig. 3 General scheme of current proteo-
mic-flow trough, for clinical metabolic
research. Human body fluids (i.e. sera,
urine and blood) have to be properly
stored and prepared with optimised proto-
cols. Subsequently, the proteins should be
purified and/or isolated to get digested
peptides (i.e. using trypsin). The adequate
proteomic-MS based strategy is applied,
and once we get the data (potential bio-
markers), validation assays (i.e. ELISA
and/or western blotting) can be carried
out choosing specific antibodies to iden-
tify real protein-biomarkers. Currently,
clinical proteomics research involves high-
performance chromatography coupled to
mass spectrometry avoiding 2DE-gels to
identify high and low abundant proteins in
a given clinical sample.
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with complications and proteins E5, E6 and E7 are indicators of good
prognosis. These candidate biomarkers can be routinely monitored in
each patient to get more information about how to improve the treat-
ment, regime and their prognosis.
In 2009 Kim et al. [83] carried out proteomic analysis in ob/ob
mice, which lack leptin, before and after hypoglycaemic polysaccha-
ride treatments. Their goal was to identify biomarkers of DM2 prog-
nosis using 2DE-gel electrophoresis (2-DE). Specifically, these
authors studied the influence of hypoglycaemic extracellular polysac-
charides (EPS) coming from the macrofungus Tremella fuciformis on
the differential levels of plasma proteins in ob/ob mice via 2-DE. They
were able to visualize 900 spots of which 92 were differentially regu-
lated in ob/ob mice. From these 92 spots, 40 were identified to be rel-
evant diabetes-associated proteins. Furthermore, they were able to
corroborate that high serum level of ferritin, which acts as an antioxi-
dant via binding the iron-excess, is a risk factor for future-DM2, and
that adiponectin plays an important role in the metabolic syndrome
and inflammation, as low serum levels of adiponectin are a risk ele-
ment for DM2. They also demonstrated that Apo A-I, IV, C-III, E, reti-
nol-binding protein 4 and transferrin proteins were significantly
altered in ob/ob mice, and their levels were normalized after EPS
treatment. Through western blot, they observed that while resistin is
up-regulated, adiponectin is down-regulated in diabetes and obesity
and this was normalized with EPS. Moreover, to complement the
resulting proteomics data, Kim et al. [83] investigated the differential
gene expression patterns in different tissues, such as liver, adipose
tissue and muscle of ob/ob mice in response to EPS treatment, by
use of PCR arrays. The resulting data demonstrated that the expres-
sion level of many genes related to the onset, development and pro-
gression of diabetes was significantly down-regulated by EPS
therefore suggesting that EPS might act as a potent regulator of gene
expression for a wide variety of genes in ob/ob mice, particularly in
obesity, insulin resistance and complications from diabetes mellitus
[83]. Thus, Kim et al. [83] successfully coupled different OMIC tools
to improve and corroborate the resulting data.
It is well-known that obesity and ageing affect adipocyte metabo-
lism and the distribution of fat in subcutaneous and visceral depots.
Moreover, weight gain and ageing can lead to similar clinical out-
comes as, for example, insulin resistance, cardiovascular disease and
atherosclerosis. Alfadda et al. [84] studied the expression level of
proteins in obese patients in relation to their subcutaneous adipose
tissues and age. Through 2DE-DIGE coupled to MALDI-TOF these
authors were able to identify 9 highly expressed proteins and 4 lower
expressed proteins in adipocytes from old compared to young obese
patients. Some of the more highly expressed proteins include: (A1)
prohibitin 1, (A2) protein disulphide isomerase A3, (A3) beta actin,
(A4) profilin, (A5) aldo-ketoreductase 1 C2, (A6) alpha crystallin B
and (A7) the annexins A1, A5 and A6. The 4 less abundant proteins
are: (B1) keratin type 2 cytoskeletal 1, (B2) keratin type 2 cytoskeletal
10 and (B3) haemoglobins A and B. These are involved in regulation
of apoptosis, cellular senescence and inflammatory responses, all of
which are common pathologic events in obesity and ageing. In addi-
tion, signal transducer and activator of transcription (STAT) 3 was
identified as the central molecule in the connectivity map and the
apoptotic pathway as the pathway with the highest Mascot score:
(Mascot is a search engine which uses MS data to identify proteins
from primary sequence databases, as the resulting digest peptide mix-
ture is analysed by the sequence from MS as described above) (http://
www.matrixscience.com/search_form_select.html). Differences in the
abundances of prohibitin 1, protein disulphide isomerise A3, beta
actin, profilin and STAT3 proteins were validated via immunoblotting.
The data resulting from the studies by Alfadda et al. demonstrated
that the proteins identified to be differentially expressed in aged obese
versus young obese patients suggest an increase in resistance to
apoptosis as a defence mechanism against a state of chronic low-
grade inflammation. They also state that their data provide clues for
unravelling the biochemical mechanisms underpinning obesity and
obesity-related ageing [84].
Recently many researchers have begun to use MS-based quanti-
tative tools (i.e. iTRAQ) instead of 2DE or 2DE-DIGE. The main advan-
tage is that MS-based quantification allows measurements via adding
isotopes labels; thus more proteins, including low expressed proteins,
can be quantified. Mass spectrometry-quantitative studies using
iTRAQ in DM2 represent a good possibility for meeting the challenge
of improving the data collected to date, as it belongs to a very refined
proteomic strategy.
A relevant example is the study of Cai et al. [85] who analysed
cardiomyopathy and DM2 with the iTRAQ proteomic approach. Dia-
betic cardiomyopathy accompanying T2DM is a complicated disorder
caused by a multifactorial pathology including altered cardiac energy
metabolism and increased oxidative stress. Obesity is associated with
high levels of circulating fatty acids, which can result in increased
fatty acid uptake and TG accumulation in the myocardium. Further-
more, increased oxygen damage and generation of reactive oxygen
species (ROS) augment cardiac damage. Thus, normalization of car-
diac energy metabolism and reduction in oxidative stress may be
important factors in the treatment of diabetic cardiomyopathy. Phlori-
zin has been reported to have an anti-diabetic effect because of its
antioxidant properties. Although phlorizin is an antioxidant used in
treating DM, its cardio-protective effects on diabetic cardiomyopathy
are not well established. Through iTRAQ high throughput proteomics
Cai et al. studied the function of phlorizin in preventing diabetic car-
diomyopathy in db/db mice, which are obese and diabetic because of
a defect in the leptin receptor. They coupled LC-MS/MS to iTRAQ to
identify and characterize the protein profiles of phlorizin-treated and
untreated db/db mice. Heart tissue from treated and untreated mice
was prepared for iTRAQ analysis to obtain the protein-profile pattern
of phlorizin’s effect on myocardial proteins. A total of 1627 proteins
were identified. Of the 113 differentially expressed proteins, 29 were
elevated in the db/db group compared with the control group, but
were decreased by phlorizin treatment. An additional 84 proteins were
decreased in the db/db mice compared with the control group. The
authors selected 2 proteins (calnexin and integrin-linked protein
kinase) for western blotting analysis to validate the iTRAQ data. Caln-
exin was found to be decreased, whereas integrin-linked protein
kinase was increased in the phlorizin treated DM group compared
with the DM group. Quantification of the band intensity showed that
the results were consistent with the iTRAQ data.
Cai et al. [85] were able to identify thousands of proteins of which
12–15% were differentially expressed. These proteins are involved in
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cardiac lipid metabolism, mitochondrial function and cardiomyopathy.
The resulting data suggests that phlorizin may prevent the develop-
ment of diabetic cardiomyopathy by regulating the expression of key
proteins in these processes. They also showed that phlorizin signifi-
cantly decreases body weight-gain and circulating levels of glucose,
triglycerides, total cholesterol and glycosylated-end products. Their
findings suggest that normal myocardial structure was better pre-
served after phlorizin treatment and that this drug can be a novel ther-
apeutic protocol for the treatment of diabetic cardiomyopathy, with
the proteomic data helping to identify the possible mechanism [85].
Adipocytes play a central role in energy metabolism and in the
obesity epidemic. Therefore, determining the protein composition of
adipocytes should help to unravel important biological questions. In
such an endeavour, Mann et al. [86] studied the adipocyte-proteome
by proteomics plus mass spectrometry and bioinformatic tools. They
first carried out subcellular fractionation of the mouse preadipocyte
cell line 3T3-L1 with and without insulin treatment, into cytosol,
membrane, mitochondria and nuclear fractions. They used SDS-PAGE
gels from which the protein-bands were digested and the resulting
peptides were identified via LC-MS/MS/MS (LTQ-FT). They were able
to identify 3287 proteins that form part of the adipocyte proteome.
Moreover, each fraction was analysed by western blotting and using
specific antibodies for each fraction. In addition, they validated all
resulting data by bioinformatics, obtaining one of the largest high
confidence proteomes reported. The adipocyte-proteome is available
in the Max-Planck Unified Proteome database [86]. This article con-
tains very useful information to unravel the complexity of the adipo-
cyte in obesity and other pathologies [86].
Another example from the group of Mann et al. [87] is related to
unravelling the insulin induced intracellular signalling pathway via
phosphoproteomics. It is well-known that the insulin signalling path-
way is very important in metabolic diseases and cellular processes of
ageing. The insulin receptor and its substrates are fundamental in the
insulin signalling-network, with insulin binding to its receptor to trig-
ger tyrosine phosphorylation cascades that subsequently activate
other connected cascade networks. Understanding the activation of
connected signalling networks is the key to unravelling diverse bio-
logical processes related to DM and obesity. To begin to understand
the network of the tyrosine phosphorylation cascade, Mann et al.
identified the tyrosine-phosphoproteome of the insulin signalling
pathway by applying MS coupled to phosphotyrosine immunoprecipi-
tation and SILAC in differentiated brown adipocytes. They also quanti-
fied the temporal dynamics of tyrosine phosphorylation events upon
insulin stimulation in differentiated brown adipocytes. The authors
applied high resolution quantitative MS-based proteomic tools (SILAC
and anti-pY immunoprecipitation) to identify and quantify 40 protein
effectors from the insulin pathway in differentiated brown adipocytes.
To know the temporal dynamics of phosphorylation of proteins on
tyrosine, the authors applied a triple label of SILAC with three differ-
entially labelled cell populations being stimulated for different times.
Data were corroborated by western blotting. From the 40 insulin ef-
fectors identified, 7 (SDR, PKC binding protein, LRP-6 and PISP/
PDZK11, a potential calcium ATPase binding protein) were described
for the first time to be involved in insulin signalling. In addition, Mann
et al. indicate that this approach is capable of detecting the specific
pY containing proteins/peptides-and quantify the level of their phos-
phorylation according to different stress and stimuli conditions over
insulin network [87].
Walker et al. [88] have recently suggested that in obesity the ‘net-
works’ of metabolic signalling pathways are related to vitamin D
status and that vitamin D regulation of adiponectin involves post-
translational-events. They coupled 2DE-gels plus MS to identify rele-
vant molecules in obese children dichotomized according to 25OH
vitamin D (25OHD) levels. Platelet–free plasma from 42 obese chil-
dren (M/F = 18/24) classified according to their 25OHD3 levels
(<15 ng/ml = deficient and >30 ng/ml = non-deficient) was analy-
sed. Image analysis (ChemiDoc Imager and PD Quest –software to
analyse the resulting proteomic data-) was able to identify the pro-
tein-spots from 2DE-Sypro-gels that were differentially expressed
according to each individual spot ‘volume’ via density/area integrating
Sypro-Ruby staining to the Gaussian model. Their data showed 53
differentially expressed protein-spots, from which 51% were down-
regulated (comparing VD deficiency and no deficiency of VD). One
interesting identified biomarker is the HMW form of adiponectin,
which was observed to be down-regulated in obese paediatric
patients with vitamin D deficiency. Additionally, the identified biomar-
kers are able to be modulated in vivo with vitamin D supplementation.
This proteomic approach represents a very interesting strategy to dif-
ferentiate phenotypes of diseases and also to study specific therapy
targets.
An important contributing factor for obesity and its associated
comorbidites is a sedentary lifestyle, in addition to excessive food
intake. Abu-Farha et al. [89] recently published an interesting study
applying high-through-put proteomic analyses of peripheral blood
mononuclear cells (PBMCs). The PBMCs samples were purified from
lean and obese human males to identify and quantify differentially
expressed proteins between both groups. In this study the mecha-
nisms underlying obesity progression and the possibility of managing
this progression with physical exercises were analysed. Using SCX
plus MS/MS, 47 proteins differentially expressed between lean and
obese patients were identified [89]. Thrombospondin 1 (TSP1) was
up-regulated while histone deacetylase 4 (HDAC4) was down-regu-
lated and after 3 months of physical exercises, TSP1 and HDAC4
returned to control levels.
Omega-3 polyunsaturated fatty acids (n-3 PUFA) are reported to
decrease the symptoms of diabetes, obesity and insulin resistance
related to the metabolic disorders. The proteins and pathways
involved in the regulation of n-3 PUFA are unknown, especially those
which produce beneficial health effects. Ahmed et al. [90] studied the
effect of diets with high or low levels of n-3 PUFA on hepatic proteo-
mic profile in mice. They applied 2DE-gels coupled to LC-MS/MS
analysis plus specific software (ImageScanner III; Progenesis Same-
spots, version 3.1). It is important to note that 800 lg of total protein
needed to be loaded into 2DE-gels (it is now possible to use other
proteomic tools, mentioned above, to avoid the necessity of using
such a large amount of sample). The resulting protein-spots visual-
ized via 2DE were digested with trypsin and analysed by MALDI-TOF
(MS). They also carried out analysis by tandem mass spectrometry
via LC-MS/MS to identify protein-spots from the 2DE-gels. MALDI-
TOF MS is useful to study specific or a reduced number of protein-
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spots, while when using LC-MS/MS, a greater number of protein-
spots can be more rapidly identified. They found that a diet rich in n-3
PUFA decreases the expression of regucalcin, adenosine kinase and
aldehyde dehydrogenase. In addition, diets rich in n-3 PUFA increase
the expression of apolipoprotein A-I, S-adenosylmethionine synthase,
fructose-1, 6-bisphosphatase, ketohexokinase, malate dehydroge-
nase, GTP-specific succinyl CoA synthase, ornithine aminotransferase
and protein disulfide isomerase-A3. Thus, these authors showed that
n-3 PUFA produces modifications in many proteins related to regula-
tion of lipids, carbohydrates, the citric acid cycle and protein metabo-
lism and promoting the hypothesis that there is a network of
metabolic pathways affected by n-3 PUFA [90] (Table 1 shows exam-
ples of diabetes and obesity studies using proteomic tools: the type
of sample and the clinical and proteomic goals are detailed, in addi-
tion the identified proteins/biomarkers, including the proteomic
approach, are mentioned [91–102]). Martos-Moreno et al. [103] eval-
uated the ability of serum proteomic analysis to detect the metabolic
alterations compared to standard clinical assays, and also to identify
potential new candidate biomarkers from metabolic impairment in
very young obese children. They discovered that isoforms of apolipo-
protein-A1, apo-J/clusterin, vitamin D binding protein and transthyre-
tin were down-regulated via 2DE coupled to MALDI-TOF (MS, MS/
MS) in young obese patients with some changes in these proteins
being enhanced by insulin resistant and partially reversed after weight
loss.
Interestingly, they observed that low molecular weight isoforms
of haptoglobin were increased in obese patients, enhanced in insulin
resistant obese children and again decreased after weight loss, being
positively correlated with serum interleukin-6 and NAMPT/visfatin lev-
els. The significance for a potential candidate biomarker was con-
firmed statistically for low molecular-weight isoform haptoglobin
(obese versus control and insulin-resistant versus non-insulin-resis-
tant) and Apo A1 (IR versus non-IR). Indeed, apolipoprotein-A1 and
haptoglobin were validated via ELISA to confirm the clinical signifi-
cance of those potential biomarkers related to metabolic complica-
tions in young obese children.
This research study establishes the base or substructure of
proteomic utilities for obesity clinical improvements, to identify, in
the near future, true candidate biomarkers may help to improve
therapies at the early onset of obesity and insulin resistance in
childhood [104].
List et al. [105] carried out proteomic analysis on the skin of
C57BL/6J mice with type 2 diabetes using non-diabetic mice as con-
trols. To induce obesity and diabetes, authors applied high fat diet to
mice during 16 weeks. They applied 2DE and PDQuest software for
the analysis getting around 1000 distinct protein spots. From those
1000 spots, 6 were shown to be significantly decreased while 22
were over-expressed in the diabetic state compared to controls.
These analyses were carried in a MALDI-TOF in MS and MS/MS
mode. List et al., observed that around 60% of the proteins that
were up and/or down-regulated, belong to energy metabolism. The
sample analysed in this study was diabetic skin, and it provides the
identification of proteins from mouse-skin samples related to
changes in obesity and subsequent diabetes. In addition, the authors
remark on the relevance of skin biopsies coupled to proteomic
assays as a very useful tool non-invasive for diagnoses of hyperin-
sulinemia and diabetes [105].
Kopchick et al. [104] remarked in at the beginning of 2009 on the
use of proteomics in general for blood, urine and tissue analyses for
the discovery of new growth hormone (GH) induced serum biomar-
kers. They discovered that isoforms of tranthyretin, clusterin, ApoE
and ApoA1 are differentially expressed via MS and MS/MS coupled to
2DE-gels, thus these isoforms may be potential biomarkers for initiat-
ing studies using recombinant human growth hormone (rhGH). In
addition, they suggest that with more biomarkers, it is possible to
develop a robust, sensitive and specific test system for rhGH using a
combination of multiple markers, thus achieving new targets and
therapy improvements.
The detection of rhGH is difficult as it has a short half-life, thus,
Kopchick et al. [106] indicate that novel and robust biomarkers of to
detect rhGH abuse are needed. Through 2DE and MS, specific iso-
forms of alpha-1 antitrypsin and transthyretin were observed to be
increased; while inter-alpha-trypsin inhibitor heavy chain H4, apolipo-
protein A-1 and haemoglobin beta chain were observed to be
decreased. The resulting data shows that high dose rhGH administra-
tion significantly reduced total serum protein concentrations and up-
or down-regulated specific isoforms of five serum proteins. These
protein isoforms may serve as potential biomarkers of rhGH treat-
ment including when rhGH is misused and abused. For this study,
serum samples- derived from the patients treated with rhGH in a ran-
domized, double-blind, placebo-controlled-design were analysed. In
addition, the biological meaning resulting from MS data was validated
by western-blotting assays. Table 1 summarizes useful metabolic
research examples carried out via different proteomics strategies
(Table 1).
It is obvious that the current international human proteome
sequencing programme (http://www.thehpp.org/human proteome
project HUPO) will have an important impact on the diagnoses of
diseases and the innovation of therapies [107–109]. It has been
predicted that the complete human proteome will be fully
sequenced in less than 2–3 years; thus several chronic diseases,
such as diabetes, obesity and/or ageing, will benefit from proteo-
mics research [110]. Therefore, reference map of the human pro-
teome useful for many pathologies will be available, thus
facilitating the use of proper controls for each clinical study [110],
as it is very important to choose proper patients and good con-
trols for independent verification, especially when looking for real
protein biomarkers for improvements in diagnoses and therapies
[111].
Concluding remarks
The molecular mechanisms underlying obesity and its progression
to DM2 are not completely known. Proteomics and other OMICs
tools are helping to advance our understanding of the origin,
onset, development, prevention and treatment of complex diseases
including obesity and DM2. Moreover, as proteomics-MS-based
technologies are becoming more sensitive and specific, employ-
ment of these tools is an important opportunity to augment our
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knowledge of DM2 and obesity and identify new targets for diag-
nosis and treatment.
Liquid chromatography-mass spectrometry results in increased
accuracy compared to 2DE-gels, especially because of the fact that
LC-MS allows identification of low expressed proteins (good protein
candidate biomarkers). Thus, although important information has
been achieved via 2DE (especially concerning isoforms studies), new
concepts can be reached when analysing clinical samples via proteo-
mic approaches that directly apply LC-MS avoiding 2DE.
The new possibilities of proteomic strategies, which include SI-
MAC, iTRAQ, label-free and nano-ESI-LC-MSn, could result in the
identification of new phosphorylated biomarkers in the intracellular
signalling networks involved in DM and obesity. It should be empha-
sized once more that correct clinical sample preparation is an essen-
tial pre-requisite and this should be standardized in biobanks.
To finalize, the advances in proteomic approaches and the com-
plete sequence of the human proteome, will allow us to unravel
changes in the proteomic profile of clinical samples from obese
patients with and without diabetes, as well as DM2 with and without
obesity (Fig. 4 summarizes the pros and cons (tips) of several prote-
omic methodologies useful for metabolic research). Thus, it will bene-
fit the patients and help to advance specific therapies. As a delegate
of HUPO (http://www.hupo.org/; Fostering international proteomic ini-
tiatives to better understand human disease), for human proteome on
children assays and studies at Hospital Universitario Ni~no Jesus
(Madrid, Spain), we are seeking to support the human proteome in
this context. We envision this will further benefit the understanding of
the pathology of the diseases and ultimately improve the diagnoses
and personalized treatments in the near future; thus, patients will
undoubtedly be benefited.
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